MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

UPDATE ON THE POTENTIAL DISPOSAL OF EQUITY INTEREST IN SHANGHAI MICROPORT ORTHOPEDICS CO., LTD.

The Transaction

Reference is made to the announcement of the Company dated 15 July 2026 in relation to the Transaction.

On 29 July 2026, Suzhou MicroPort (a subsidiary of the Company and one of the Target Company Shareholders), the Other Target Company Shareholders and Tinavi entered into the Agreement, pursuant to which Suzhou MicroPort, together with the Other Target Company Shareholders, conditionally agreed to sell a total of 62% equity interest in the Target Company (of which Suzhou MicroPort conditionally agreed to sell approximately 44.29% equity interest in the Target Company) to Tinavi at a price to be agreed with reference to the appraisal value of the Subject Assets. The final consideration for the Subject Assets will be determined upon completion of the appraisal of the Subject Assets and such consideration shall be set out in the supplemental agreement to be entered into by the relevant parties. As consideration, Tinavi will issue a corresponding number of Consideration Shares to each of the Target Company Shareholders at the Issue Price of RMB14.36 per Consideration Share (subject to adjustments set out in the Agreement). The number of Consideration Shares to be issued to each of the Target Company Shareholders will be calculated by dividing the final consideration for the Subject Assets by the Issue Price.

As at the date of the Agreement, the Target Company, in which Suzhou MicroPort holds approximately 82.29% equity interest, was accounted for as a subsidiary of the Company. If the Transaction is materialised, Suzhou MicroPort will hold a 38.00% equity interest in the Target Company, and the Target Company and its subsidiaries will cease to be accounted for as subsidiaries of the Company.

Implications under the Listing Rules

Based on the information available to the Company as at the date of this announcement, the Company estimated that the highest applicable percentage ratio for the Transaction may be 5% or more but is expected to be less than 25%, and the Transaction may therefore constitute a discloseable transaction of the Company, and may be subject to the reporting and announcement but not the shareholders' approval requirements under Chapter 14 of the Listing Rules. The final transaction classification and compliance requirements will be determined based on the final consideration of the Subject Assets to be transferred by Suzhou MicroPort to Tinavi and the number of Consideration Shares to be issued by Tinavi to Suzhou MicroPort.

The Company will comply with the applicable provisions of Chapter 14 of the Listing Rules and issue further announcement(s) regarding (among others) the appraisal value of the Subject Assets, the final consideration for the Subject Assets to be transferred by Suzhou MicroPort to Tinavi, the number of Consideration Shares to be issued by Tinavi to Suzhou MicroPort and any other arrangements in due course.

As the Transaction is subject to the satisfaction and/or waiver of the relevant conditions precedent and may or may not proceed, shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

Reference is made to the announcement of the Company dated 15 July 2026 in relation to the Transaction.

On 29 July 2026, Suzhou MicroPort (a subsidiary of the Company and one of the Target Company Shareholders), the Other Target Company Shareholders and Tinavi entered into the Agreement, pursuant to which Suzhou MicroPort and the Other Target Company Shareholders conditionally agreed to sell, and Tinavi conditionally agreed to acquire, a total of 62% equity interest in the Target Company. As consideration, Tinavi will issue a corresponding number of Consideration Shares to each of the Target Company Shareholders.

Principal Terms of the Agreement

The principal terms of the Agreement are set out below:

Parties

1) Suzhou MicroPort (a subsidiary of the Company and one of the Target Company Shareholders);

2) the Other Target Company Shareholders; and

3) Tinavi.

Conditions to the effectiveness of the Agreement

The Agreement shall be concluded after being executed and sealed by all parties thereto and the operative provisions of the Agreement shall only become effective upon the fulfillment or satisfaction of the conditions stipulated therein, including but not limited to the approval of the Transaction by the board and general meeting of Tinavi, the internal approval of the Transaction by the Target Company Shareholders, the approval of the SSE and the CSRC in respect of the Transaction and the other approvals as required by applicable laws and regulations (if any).

Subject Assets and Consideration

Tinavi intends to acquire 62% equity interest in the Target Company from the Target Company Shareholders by the issuance of the Consideration Shares.

The equity interest in the Target Company held by each of the Target Company Shareholders as at the date of the Agreement, and the equity interest in the Target Company to be transferred by each of the Target Company Shareholders to Tinavi, are as follows:

	Registered capital held by the relevant Target Company Shareholder as at the date of the Agreement *(RMB)*	**Percentage of equity interest in the Target Company held by the relevant Target Company Shareholder as at the date of the Agreement** *(%)*	**Registered capital to be transferred by the relevant Target Company Shareholder to Tinavi** *(RMB)*	**Percentage of equity interest in the Target Company to be transferred by the relevant Target Company Shareholder to Tinavi** *(%)*
Suzhou MicroPort	2,040,695,556	82.2861	1,098,295,556	44.2861
Target Company Shareholder A	179,111,111	7.2222	179,111,111	7.2222
Target Company Shareholder B	110,222,222	4.4444	110,222,222	4.4444
Target Company Shareholder C	96,444,444	3.8889	96,444,444	3.8889
Target Company Shareholder D	53,526,667	2.1583	53,526,667	2.1583
Total	**2,480,000,000**	**100.0000**	**1,537,600,000**	**62.0000**

The consideration for the transfer of the Subject Assets shall be determined through the negotiation among the parties with reference to the appraisal value of the Subject Assets as set out in the asset appraisal report to be issued by an independent third-party asset appraisal institution, and a supplemental agreement will be executed by the parties to specify the details upon finalization.

Proposal for the Transaction

The specific proposal for the Transaction is as follows:

1) Class, Nominal Value and Place of Listing of the Consideration Shares

The Consideration Shares shall be domestic listed RMB ordinary shares (A shares) of Tinavi, with a nominal value of RMB1.00 per share, and the place of listing shall be the SSE.

2) Method of Issuance and Target Subscribers

The method for issuance shall be issuing shares to specific target subscribers, who will be the Target Company Shareholders.

3) Issue Price Benchmark Date and Issue Price

a) Issue Price Benchmark Date and Issue Price

The Issue Price Benchmark Date for the Transaction shall be the Tinavi Board Announcement Date.

The Issue Price shall be determined on the principle that it is not less than 80% of the average trading price of the shares of Tinavi in the 20 trading days preceding the Issue Price Benchmark Date. As agreed among the parties, the Issue Price will be RMB14.36 per Consideration Share (subject to adjustments set out in the Agreement and mentioned below).

b) Adjustments to the Issue Price

For the purpose of addressing the potential adverse impact of share price fluctuations arising from capital market volatility and industry-specific factors on the Transaction, the parties to the Agreement have agreed to adopt a bidirectional issue price adjustment mechanism. During the Issue Price Adjustment Period, if the following triggering conditions are met, Tinavi's board of directors shall have the right to convene a board meeting to decide whether to adjust the Issue Price:

(i) Downward Adjustment

During the Issue Price Adjustment Period, a downward adjustment shall be triggered if both of the following conditions are met simultaneously on any trading day:

A) The Sci-Tech Innovation Board Composite Index (000680.SH) or Shenwan Medical Device Index (801153.SI) is lower than the closing index on the trading day prior to the date of the announcement of the board resolution of Tinavi at which the Transaction was first considered by more than 20% for at least 20 trading days out of the 30 consecutive trading days prior to any trading day; and

B) Tinavi's closing price is lower than its closing price on the trading day prior to the date of the announcement of the board resolution of Tinavi at which the Transaction was first considered by more than 30% for at least 20 trading days out of the 30 consecutive trading days prior to any trading day.

(ii) Upward Adjustment

During the Issue Price Adjustment Period, an upward adjustment will be triggered if both of the following conditions are met simultaneously on any trading day:

A) The Sci-Tech Innovation Board Composite Index (000680.SH) or the Shenwan Medical Device Index (801153.SI) is higher than the closing index on the trading day prior to the date of the announcement of the board resolution of Tinavi at which the Transaction was first considered by more than 20% for at least 20 trading days out of the 30 consecutive trading days prior to any trading day; and

B) Tinavi's closing price is higher than its closing price on the trading day prior to the date of the announcement of the board resolution of Tinavi at which the Transaction was first considered by more than 30% for at least 20 trading days out of the 30 consecutive trading days prior to any trading day.

(iii) Issue Price Adjustment Mechanism

During the Issue Price Adjustment Period, Tinavi may and may only adjust the Issue Price of the shares to be issued in connection with the Transaction once. If Tinavi's board of directors decides to adjust the Issue Price, the Issue Price Adjustment Benchmark Date will be used as the new Issue Price Benchmark Date for determining the adjusted Issue Price for the Transaction. The Issue Price shall be adjusted to no less than 80% of the average trading price of Tinavi's shares over the 20, 60, or 120 trading days prior to (excluding) the Issue Price Adjustment Benchmark Date. The adjusted Issue Price will be determined in writing through mutual agreement between the parties to the Agreement, and will not need to be further approved at Tinavi's shareholders meeting.

During the period between the Issue Price Benchmark Date (or the Issue Price Adjustment Benchmark Date, as applicable) and the Completion Date of Issuance, if there are any ex-rights or ex-dividend events of Tinavi, such as distribution of dividends, issue of bonus shares, share allotment or capital reserve capitalization, the Issue Price will be adjusted accordingly.

4) Number of Consideration Shares to be Issued

The number of Consideration Shares to be issued equals the consideration for the Subject Assets divided by the Issue Price. The final number of Consideration Shares to be issued shall be finally determined in a supplemental agreement to be entered into subsequently, and shall be subject to approval by the shareholders' meeting of Tinavi and registration by the CSRC. In the event that the Issue Price is adjusted pursuant to the events set out in the Agreement as mentioned above, the number of Consideration Shares to be issued shall be adjusted accordingly.

5) Lock-up Arrangement

a) Suzhou MicroPort shall not transfer the Consideration Shares until the later of (1) the date falling thirty-six months following the completion of the issuance of the Consideration Shares in connection with the Transaction (or, if the share issuance is to be carried out in stages, the date of completion of the issuance of the first tranche of shares); and (2) the date of public disclosure of the financial data for the accounting year in which the Target Company achieves a positive net profit.

b) The Other Target Company Shareholders shall not transfer the Consideration Shares within 12 months from the date of completion of the issuance of the Consideration Shares in connection with the Transaction provided that if the relevant Other Target Company Shareholder has held the relevant Subject Assets for less than twelve months before the date of completion of the issuance of the Consideration Shares in connection with the Transaction, such Other Target Company Shareholder shall not transfer the Consideration Shares within 36 months from the date of completion of the issuance of the Consideration Shares in connection with the Transaction.

c) During the aforesaid lock-up period, any additional shares received by the Target Company Shareholders derived from the Consideration Shares as a result of issue of bonus shares, share allotment or other actions of Tinavi shall also be subject to the aforementioned lock-up period restrictions.

d) Upon the expiry of the aforementioned lock-up period, the transfer and trading of the shares of Tinavi by the Target Company Shareholders shall be conducted in accordance with the relevant provisions of the CSRC and the SSE.

6) Arrangement of Accumulated Undistributed Profits

Upon the completion of the issuance of the Consideration Shares in connection with the Transaction, all the existing and new shareholders of Tinavi upon the Completion Date of Issuance will be entitled to the accumulated undistributed profits of Tinavi as of the Completion Date of Issuance in proportion to their respective shareholdings in Tinavi.

7) Attribution of Profits or Losses of the Subject Assets during the Transition Period

The arrangements regarding the profits and losses of the Subject Assets during the transition period shall be agreed upon by the parties through a supplemental agreement to be entered into after the completion of the audit and valuation work in connection with the Transaction.

Completion

Within 30 working days upon the fulfillment or satisfaction of all the conditions precedent to the effectiveness of the Agreement, the Target Company Shareholders shall cooperate with Tinavi and the Target Company to complete the industrial and commercial registration procedures of the transfer of the Subject Assets to Tinavi.

The relevant payment arrangements in respect of the Transaction by way of the issue of Consideration Shares shall be agreed between Tinavi and the parties in a supplemental agreement.

As at the date of the Agreement, the Target Company, in which Suzhou MicroPort holds approximately 82.29% equity interest, was accounted for as a subsidiary of the Company. If the Transaction is materialised, Suzhou MicroPort will hold a 38.00% equity interest in the Target Company, and the Target Company and its subsidiaries will cease to be accounted for as subsidiaries of the Company.

REASONS FOR AND BENEFITS OF THE TRANSACTION

The Target Group possesses a line of high-performance joint replacement prostheses products and well-established marketing channels developed over many years of serving overseas orthopedic markets, while Tinavi has deep expertise and a leading position in the field of orthopedic surgical robots. The business synergies, strategies, and long-term goals of both parties are highly aligned. The Transaction is expected to integrate their respective strengths and resources to form a powerful partnership, unleashing synergies far exceeding those achievable through independent operations, thereby continuously enhancing the scale, profitability and risk resilience of Tinavi and the Target Group in the orthopedic field and increasing the long-term investment value of the Group in the Target Group's business.

The Directors consider that the orthopedic business is expected to achieve improved performance and an optimised balance sheet through the Transaction, thereby enhancing the overall financial performance of the Group. In addition, the Group has, during the year, prudently arranged and optimised its debt terms and structure through various measures such as swaps and waivers, which will further improve the Group's operations and development.

The Directors consider that the terms of the Agreement are on normal commercial terms, fair and reasonable, and are in the interests of the Company and its Shareholders as a whole.

As of the date of this announcement, the audit and valuation work of the Target Company is yet to be completed and the appraisal value and pricing of the Subject Assets are yet to be confirmed. The final consideration for the transfer of the Subject Assets and the number of Consideration Shares to be issued will be agreed and confirmed by way of a supplemental agreement, and the Board will further review and, if thought fit, approve the supplemental agreement.

INFORMATION ON THE TARGET COMPANY

As at the date of the Agreement, the Target Company, in which Suzhou MicroPort holds approximately 82.29% equity interest, was accounted for as a subsidiary of the Company. The Target Company is the operating entity for the Group's international (non-China) orthopedics business.

The Target Group is principally engaged in the hip and knee orthopedic reconstruction business in overseas markets such as the United States, Japan and Europe. The Target Group has years of extensive expertise in the orthopedic field, focusing on the research, development, production, and sales of high-quality, innovative hip and knee joint products that have been thoroughly clinically validated. It has established a mature, largescale overseas sales network. Its representative product, medial pivot knee prostheses, has accumulated more than 20 years of clinical application experience. According to research findings published in The Knee[1], the Target Group's medial pivot knee prostheses achieved a 17-year cumulative prosthesis retention rate of 98.8% and a patient satisfaction rate of 95%.

As of the date of this announcement, the registered capital of the Target Company is RMB2,480 million. Suzhou MicroPort and the Other Target Company Shareholders hold approximately 82.29% and 17.71% equity interests in the Target Company respectively.

According to the consolidated financial statements (unaudited) prepared by the Target Company in accordance with the China Accounting Standards for Business Enterprises, as at 31 March 2026, the consolidated total assets of the Target Company amounted to approximately RMB2,259.39 million, the consolidated total liabilities of the Target Company amounted to approximately RMB1,947.09 million, and the consolidated owner's equity of the Target Company amounted to approximately RMB312.30 million. The consolidated loss before and after tax of the Target Company for the two years ended 31 December 2024 and 2025 are as follows:

	For the year ended 31 December 2024 *(In approximately RMB million)* (Unaudited)	**For the year ended 31 December 2025** *(In approximately RMB million)* (Unaudited)
Loss before tax	78.83	105.85
Loss after tax	95.80	104.73

Note: The above financial data have not yet been audited by the auditor engaged by Tinavi in connection with the Transaction

(1) A long term clinical outcome of the Medial Pivot Knee Arthroplasty System. George A. Macheras, et al. The Knee. 2017. 24(2): 447-453

INFORMATION ON TINAVI

Tinavi is a joint stock limited company established in the PRC and the shares of which are listed on the SSE (stock code: 688277). Tinavi, together with its subsidiaries, is a leading company in the orthopedic surgical robotics industry of the PRC, focusing on independent innovation, large-scale production, professional marketing and high-quality clinical application of orthopedic surgical robots and related technologies. Tinavi is the first in the world to launch a surgical robot platform covering the three major orthopedic fields, namely spine, joints, and trauma, enabling a single platform to address multiple indications. Its products consistently rank first in the domestic market in terms of both hospital coverage and procedure volume, and as of the end of the first quarter of 2026, the clinical application of its core product, TiRobot series of orthopedic surgical robots, had expanded to more than 200 medical institutions across 31 provinces, autonomous regions, and municipalities nationwide, with the number of surgeries performed exceeding 160,000.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, based on the latest available information, Mr. Zhang Songgen holds an aggregate of 23.42% equity interest in Tinavi through himself and the partnership enterprises controlled by him, and is the controlling shareholder and de facto controller of Tinavi. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, Tinavi and Mr. Zhang Songgen are Independent Third Parties.

INFORMATION ON THE COMPANY AND SUZHOU MICROPORT

The Company is incorporated in the Cayman Islands and the shares of which are listed on the main board of The Stock Exchange of Hong Kong Limited. The Company, together with its subsidiaries, is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally in a broad range of business segments including cardiovascular devices, orthopedics devices, endovascular and peripheral vascular devices, heart failure integrated management and cardiac rhythm management, surgical robot and other business.

Suzhou MicroPort is a company established in the PRC and is a non-wholly owned subsidiary of the Company. Suzhou MicroPort is principally engaged in the research and development, production, and sales of orthopedics devices. As at the date of the Agreement, Suzhou MicroPort holds approximately 82.29% equity interest in the Target Company and the Target Company is accounted for as a subsidiary of the Company.

INFORMATION ON THE OTHER TARGET COMPANY SHAREHOLDERS

Target Company Shareholder A is a limited liability partnership established under the laws of the PRC, which is primarily engaged in private equity investment business. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, as of the date of this announcement, the general partner of Target Company Shareholder A is Henan CICC Huirong Private Equity Fund Management Co., Ltd. (河南中金匯融私募基金管理有限公司), which is held as to 50% by CICC Capital Operation Co., Ltd. (wholly owned by China International Capital Corporation Limited, the shares of which are listed on the Shanghai Stock Exchange (601995.SH) and the Stock Exchange (3908.HK)) and as to 50% by Henan Innovation Investment Group Co., Ltd. (the ultimate beneficial owner of which is the Finance Department of Henan Province (河南省財政廳)). The partnership interest of Target Company Shareholder A is held as to 0.0988% by the aforesaid general partner, as to 35.0889% limited partnership interest by Henan Zhanxin Industry Investment Fund (Limited Partnership) (河南省戰新產業投資基金(有限合夥)) (the ultimate beneficial owner of which is the Finance Department of Henan Province (河南省財政廳)), and as to the remaining 64.8123% limited partnership interest by 18 partners, each of whom holds not more than 20% limited partnership interest.

Target Company Shareholder B is a limited liability partnership established under the laws of the PRC, which is primarily engaged in private equity investment business. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, as of the date of this announcement, the general partner of Target Company Shareholder B is Shihezi Readysun Equity Investment Mgt. Partnership Co., Ltd. (石河子睿德信股權投資管理合夥企業(有限合夥)), the ultimate beneficial owner of which is Chen Yong (陳勇). The partnership interest of Target Company Shareholder B is held as to 13.0952% by the aforesaid general partner, as to 13.75% by Lu Wei (陸威), and as to the remaining 73.1548% partnership interest by 8 limited partners, each of whom holds not more than 12.5% limited partnership interest.

Target Company Shareholder C is a limited liability partnership established under the laws of the PRC, which is primarily engaged in equity investment, investment management and asset management businesses. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, as of the date of this announcement, the general partner of Target Company Shareholder C is Yuemin Investment Private Equity Fund Management Co., Ltd. (粵民投私募基金管理有限公司), which is held as to 70% by Guangdong Private Investment Co., Ltd. (廣東民營投資股份有限公司) (which is held as to 15.6250% by Zhuhai Xianfeng Yuefu Investment Partnership (Limited Partnership) (珠海賢豐粵富投資合夥企業(有限合夥)), with the remaining 84.3750% interests held by 17 other entities, each holding no more than 13%) and as to 30% by Guangdong Yueteng Enterprise Management Partnership Enterprise (Limited Partnership) (廣東悅騰企業管理合夥企業(有限合夥) (in which Wang Yike (王義克) serves as the general partner and holds 95% limited partnership interest). The partnership interest of Target Company Shareholder C is held as to 1.3423% by the aforesaid general partner, and as to the remaining 98.6577% by 14 limited partners, each holding 7.0470% limited partnership interest.

Target Company Shareholder D is a limited liability partnership established under the laws of the PRC, which is primarily engaged in investment business and serves as an employee shareholding platform of the Group. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, as of the date of this announcement, the general partner of Target Company Shareholder D is Yu Tianbai (俞天白), the chairman and manager of Suzhou MicroPort. The partnership interest of Target Company Shareholder D is held as to 0.7563% by the aforesaid general partner directly, as to 33.6975% by Shanghai Gupan Enterprise Management Consulting Center (Limited Partnership) (上海崮盤企業管理諮詢中心(有限合夥)) (which is an employee shareholding platform, the general partner of which is Yu Tianbai (俞天白) who directly holds 0.1145% thereof, and which is held as to 36.0825% by the Company indirectly, as to 3.4364% by Xu Bin (徐彬), a director of Suzhou MicroPort, and as to the remaining 60.3666% by 28 non-director employees of the Group, each of whom holds not more than 6% interest), and as to the remaining 65.5462% partnership interest by 3 limited partners, each of whom holds not more than 24% limited partnership interest.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, save as disclosed above, each of the Other Target Company Shareholders and their respective ultimate beneficial owner(s) are Independent Third Parties.

IMPLICATIONS UNDER THE LISTING RULES

Based on the information available to the Company as at the date of this announcement, the Company estimated that the highest applicable percentage ratio for the Transaction may be 5% or more but is expected to be less than 25%, and the Transaction may therefore constitute a discloseable transaction of the Company, and may be subject to the reporting and announcement but not the shareholders' approval requirements under Chapter 14 of the Listing Rules. The final transaction classification and compliance requirements will be determined based on the final consideration of the Subject Assets to be transferred by Suzhou MicroPort to Tinavi and the number of Consideration Shares to be issued by Tinavi to Suzhou MicroPort.

The Company will comply with the applicable provisions of Chapter 14 of the Listing Rules and issue further announcement(s) regarding (among others) the appraisal value of the Subject Assets, the final consideration for the Subject Assets to be transferred by Suzhou MicroPort to Tinavi, the number of Consideration Shares to be issued by Tinavi to Suzhou MicroPort and any other arrangements in due course.

As the Transaction is subject to the satisfaction and/or waiver of relevant preconditions and may or may not proceed, shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meaning:

"Agreement"	the share issue and purchase of assets agreement dated 29 July 2026 entered into between the Target Company Shareholders and Tinavi in relation to the Transaction
"Board"	the board of Directors of the Company
"Company"	MicroPort Scientific Corporation, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 00853)
"Completion Date of Issuance"	the date on which the Consideration Shares are registered in the Target Company Shareholders' share account opened with China Securities Depository and Clearing Corporation Limited (中國證券登記結算有限責任公司)
"connected person(s)"	has the meaning ascribed thereto under the Listing Rules
"Consideration Shares"	new ordinary shares of Tinavi with a nominal value of RMB1.00 each to be issued to the Target Company Shareholders pursuant to the Agreement as the consideration for the acquisition of the Subject Assets
"CSRC"	the China Securities Regulatory Commission (中國證券監督管理委員會)
"Director(s)"	the director(s) of the Company
"Group"	the Company and its subsidiaries
"Independent Third Parties"	parties who are independent of the Company and its connected persons
"Issue Price"	the issue price of the Consideration Shares, being RMB14.36 per Consideration Share (subject to adjustment upon the events specified in the Agreement)
"Issue Price Adjustment Benchmark Date"	the trading day following the first time the Issue Price adjustment trigger conditions are met during the Issue Price Adjustment Period

"Issue Price Adjustment Period"	the period from the date of the announcement of the shareholder meeting resolution of Tinavi to the date before the registration of the Transaction is obtained from the CSRC
"Issue Price Benchmark Date"	the benchmark date for determining the Issue Price
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Other Target Company Shareholders"	collectively, Target Company Shareholder A, Target Company Shareholder B, Target Company Shareholder C and Target Company Shareholder D
"PRC"	the People's Republic of China, excluding, for the purposes of this announcement only, excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan
"RMB	Renminbi, the lawful currency of the PRC
"SSE"	the Shanghai Stock Exchange
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subject Assets"	62% equity interest in the Target Company
"Suzhou MicroPort"	Suzhou MicroPort Orthopedics Scientific (Group) Co., Ltd. (蘇州微創骨科學(集團)有限公司) a company established under the laws of the PRC with limited liability, and a non-wholly owned subsidiary of the Company as at the date of the Agreement
"Target Company"	Shanghai MicroPort Orthopedics Co., Ltd. (上海微創骨科醫療科技有限公司), a company established under the laws of the PRC with limited liability, and a non-wholly owned subsidiary of the Company as at the date of the Agreement
"Target Company Shareholders"	any or all existing shareholders of the Target Company, namely Suzhou MicroPort and the Other Target Company Shareholders as at the date of the Agreement
"Target Company Shareholder A"	Qihui Runjin (Qingdao) Private Equity Investment Fund Partnership (Limited Partnership)* (啟匯潤金(青島)私募股權投資基金合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC

"Target Company Shareholder B"	Jiaxing Guanyou Yifang Venture Investment (Limited Partnership)* (嘉興觀由益方創業投資合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC
"Target Company Shareholder C"	Guangzhou Yuemintou Investment Yunhao Equity Investment (Limited Partnership)* (廣州粵民投雲浩股權投資合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC
"Target Company Shareholder D"	Shanghai Zonggu Enterprise Management Consulting Centre (Limited Partnership)* (上海縱崮企業管理諮詢中心(有限合夥)), a limited liability partnership established under the laws of the PRC
"Target Group"	the Target Company and its subsidiaries
"Tinavi"	Tinavi Medical Technologies Co., Ltd. (北京天智航醫療科技股份有限公司), a company established in the PRC whose shares are listed on the SSE (stock code: 688277.SH)
"Tinavi Board Announcement Date"	the date of the announcement of the resolutions passed at the 33rd meeting of the sixth session of the board of directors of Tinavi in which the proposals related to the Transaction were considered
"Transaction"	the transaction contemplated under the Agreement whereby Tinavi will acquire the Subject Assets from the Target Company Shareholders by the way of issue of Consideration Shares pursuant to the terms of the Agreement

As the Transaction is subject to the satisfaction and/or waiver of the relevant conditions precedent and may or may not proceed, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 29 July 2026

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purpose only*